Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

rter of 2010. U.S. sales of Byetta decreased 3 percent to $128.1 million compared with the third quarter of 2010 due to competitive pressures, while sales of Byetta and Bydureon outside the U.S. increased 18 percent to $42.9 million.

Effient®

Effient sales were $83.5 million in the third quarter of 2011, up from $71.7 million in the second quarter of 2011 due to increased demand. U.S. Effient sales were $61.4 million. Sales outside the U.S. were $22.1 million.

Animal Health

Worldwide sales of animal health products in the third quarter of 2011 were $451.0 million, an increase of 28 percent compared with the third quarter of 2010. U.S. sales grew 20 percent, to $237.9 million, due to increased demand for food animal products and the recent U.S. launch of Trifexis™. Sales outside the U.S. increased 37 percent, to $213.2 million, driven by the impact of the acquisition of certain Janssen and Pfizer animal health assets in Europe, and to a lesser extent the favorable impact of foreign exchange rates and increased demand.

2011 Financial Guidance The company has updated certain elements of its 2011 financial guidance. The company has narrowed its full-year 2011 non-GAAP earnings per share guidance to a range of $4.30 to $4.35 per share. On a reported basis, the company now expects full-year 2011 earnings per share to be in the range of $3.89 to $3.94. Earnings per share guidance excludes potential future restructuring charges.

2011 Earnings Per Share Expectations:2011
Expectations2010
Results% GrowthEarnings per share (reported)$3.89 to $3.94$4.58(14)% to (15)%In-process research and development charges
  associated with Boehringer Ingelheim
  collaboration (2011) and Acrux licensing
  agreement (2010)

.23.03Asset impairments and restructuring charges

.18.13Earnings per share (non-GAAP)$4.30 to $4.35$4.74(8)% to (9)%The company still expects total revenue to grow in th
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Declares Fourth-Quarter 2011 Dividend
2. Lilly Announces Changes in Senior Management
3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
7. Lilly Health Channel Debuts on YouTube
8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 The spinal column is one of the ... carried to and from the brain through the column control ... Injury or ailment here can be life altering, and leave ... control over their body. Though back injury and disease can ... are more options available to make things better than ever ...
(Date:8/21/2014)... - Eisai Limited is pleased to support the Canadian Epilepsy ... available in Canada . The comic book, ... children and their parents about epilepsy, the most common neurological ... 300,000 Canadians. Eisai is guided by a corporate philosophy known ... patient is central – there was a need within the ...
(Date:8/21/2014)...  Decision Resources Group finds that, for the ... and Mexico ... long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist (LAMA)- ... severe cost/coverage constraints. Therefore, new brands of LABA/LAMA ... in these countries—which will considerably expand the chronic ...
Breaking Medicine Technology:Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
... poultry ... processing plants., SHREVEPORT, La., Nov. ... poultry processing, was identified,in an October 2007 Watt Poultry USA article ... in large-scale processing plants, University of,Georgia Associate Professor of Poultry Science ...
... American Heart Association Scientific Sessions 2007 ... ... Nov. 6 ARCA Discovery, a privately held,biopharmaceutical company, announced today ... bucindolol, a,next-generation beta-blocker and vasodilator for heart failure, atrial,fibrillation, and arrhythmia, ...
Cached Medicine Technology:FreshFx Recognized for use in the Scalder as a Solution to the 'Yield/Pathogen Reduction Dilemma' 2ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 2ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 3ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 4ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 5
(Date:8/23/2014)... 2014 Hundreds of Wright hip ... of individuals who were allegedly harmed by devices ... to move forward in the U.S. District Court, ... According to an Order dated August 19th, the ... would allow the litigation’s first case to go ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
(Date:8/23/2014)... Aliso Viejo, California (PRWEB) August 23, 2014 ... plugins and themes, announced today the release of ProIntro Vol.3, ... can customize a fresh and professional tile just by dragging ... Pixel Film Studios. "ProIntro Vol.3 is a definite time saver ... is an intro pack with 30 beautifully designed titles made ...
(Date:8/23/2014)... TX (PRWEB) August 23, 2014 Youth ... of Texas. It’s no different in Houston, TX. Substance ... are falling victim to drug and alcohol dependency in ... are looking to beat substance abuse, but don’t know ... juvenile treatment facility can be a challenge because most ...
(Date:8/23/2014)... 2014 Summer vacation is almost over and ... in session. While shopping for school supplies and a new ... encourages parents and students to also spend some time brushing ... excellent hitchhikers and thrive in heavily populated places,” said Randy ... and dorms the perfect settings for bed bugs to take ...
Breaking Medicine News(10 mins):Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:Expert Advice for a Bed Bug-Free School Year 2
... ... ("CTI") (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. ... the 2009 American Society of Hematology ("ASH") Annual Meeting updated results ... pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive ...
... of Chicago have discovered a technique that is able to ... habitual snoring by screening their urine. "These findings ... test that could detect OSA in snoring children. This would ... children who snore, only about 20 to 30 percent of ...
... , OAK BROOK, Ill., Dec. 7 ... center (AMC) members for their achievements in UHC,s Supply ... are noted for modeling best practices in supply chain ... , The winners were determined using 2008 data and ...
... , , Consumers ... SILVER SPRING, Md., Dec. 6 The U.S. Food and Drug ... San Antonio Bay on or after Nov. 16 due to reports ... from this area, which is located on the Gulf of Texas. ...
... have discovered that the loss of a key segment of DNA ... to show that this kind of genetic alteration can cause obesity. ... study, led by Dr Sadaf Farooqi from the University of Cambridge ... at 300 children with severe obesity. The team scanned each ...
... find signs of feline DNA in virus , SUNDAY, Dec. 6 ... might be found in a tiger that lived thousands or millions ... virus took on a bit of a tiger,s genetic material, scientists ... to this day. That tiger, in fact, may have bitten a ...
Cached Medicine News:Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Urine test for pediatric obstructive sleep apnea possible 2Health News:Recognized Top Performers in UHC Supply Chain 2Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:AIDS May Date Back to Ancient Tiger 2
STAT-CRIT is a rapid, one-step system for measuring hematocrit....
...
Clearview C. Diff A is a one-step test for the direct qualitative detection of Clostridium difficile toxin A from fecal samples....
... one of the easiest tests to run on ... 15 minutes with no hands-on time. Critical care ... the child leaving the pediatrician's office and valuable ... to help control the spread of RSV infections. ...
Medicine Products: